David Wright’s business card may list him as a senior wealth advisor and portfolio manager, but at any given time, he could be doubling as a psychologist, life coach, crisis manager or master pu ...

David “Dave” “Thin man” Wright, 80, passed away peacefully with family by his side on Wednesday, April 30, 2025. Dave was born on September 27, 1944 in Jamestown, New York and was raised ...

The mess he left behind is Wright’s to clean up. David Blackmon is an energy writer and consultant based in Texas. He spent 40 years in the oil and gas business, where he specialized in public ...

Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...

Bell of Richardson, Texas; brother David W. Wright and his wife Talley; niece Amanda, nephew Jason and his family, nephew Craig L. Wright and his wife Anita and twin sons Caleb and Collin.

The journalist, 40, who joined the breakfast show in December, said stepping into the co-host chair beside Wright has been one ... style with former host David Koch being affectionately dubbed ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

The Eiteljorg Museum of American Indians and Western Art will feature an all-new virtual format during its 15th annual Quest for the West® Art Show and Sale, September 11-12, 2020. “Wonders of the ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

Datavant, the leading health data platform company, today announced an expanded collaboration with Boehringer Ingelheim to support the pharmaceutical company’s growing real-world evidence (RWE ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros ($ ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of ...